EQT Co-Leads $183 Million Funding Round of U.S. Biotech Electra Therapeutics

Dow Jones

Oct 22

By Dominic Chopping

STOCKHOLM--Swedish buyout group EQT co-led a $183 million series C financing round in U.S. biotechnology company Electra Therapeutics.

The financing was co-led by Nextech, with participation from new investors Sanofi, HBM Healthcare Investments, Mubadala Capital, and all existing investors.

Electra Therapeutics is developing new medicines for people with serious immunological and cancer-related diseases, with its lead product candidate, ELA026, in development to treat secondary hemophagocytic lymphohistiocytosis--a potentially fatal hyperinflammatory disease.

Proceeds from the fundraise will finance a further study of the treatment and support evaluation of the drug in blood cancers, as well as another treatment that has potential across immunology and inflammation.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

October 22, 2025 08:22 ET (12:22 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577646983"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577646983\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577646983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577646983","market":"hk","top_or_hot":-1,"title":"EQT Co-Leads $183 Million Funding Round of U.S. Biotech Electra Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  STOCKHOLM--Swedish buyout group EQT co-led a $183 million series C financing round in U.S. biotechnology company Electra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  The financing was co-led by Nextech, with participation from new investors <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, HBM Healthcare Investments, Mubadala Capital, and all existing investors. \n</p>\n<p>\n  Electra Therapeutics is developing new medicines for people with serious immunological and cancer-related diseases, with its lead product candidate, ELA026, in development to treat secondary hemophagocytic lymphohistiocytosis--a potentially fatal hyperinflammatory disease. \n</p>\n<p>\n  Proceeds from the fundraise will finance a further study of the treatment and support evaluation of the drug in blood cancers, as well as another treatment that has potential across immunology and inflammation. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2025 08:22 ET (12:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EQT Co-Leads $183 Million Funding Round of U.S. Biotech Electra Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEQT Co-Leads $183 Million Funding Round of U.S. Biotech Electra Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-22 20:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  STOCKHOLM--Swedish buyout group EQT co-led a $183 million series C financing round in U.S. biotechnology company Electra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  The financing was co-led by Nextech, with participation from new investors <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, HBM Healthcare Investments, Mubadala Capital, and all existing investors. \n</p>\n<p>\n  Electra Therapeutics is developing new medicines for people with serious immunological and cancer-related diseases, with its lead product candidate, ELA026, in development to treat secondary hemophagocytic lymphohistiocytosis--a potentially fatal hyperinflammatory disease. \n</p>\n<p>\n  Proceeds from the fundraise will finance a further study of the treatment and support evaluation of the drug in blood cancers, as well as another treatment that has potential across immunology and inflammation. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2025 08:22 ET (12:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577646983","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577646983","pubTimestamp":1761135720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"STOCKHOLM--Swedish buyout group EQT co-led a $183 million series C financing round in U.S. biotechnology company Electra Therapeutics.The financing was co-led by Nextech, with participation from new investors Sanofi, HBM Healthcare Investments, Mubadala Capital, and all existing investors.Proceeds from the fundraise will finance a further study of the treatment and support evaluation of the drug in blood cancers, as well as another treatment that has potential across immunology and inflammation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4139":"生物科技","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","NXSL":"NexTech Solutions, Inc.","BK4588":"碎股","SNY":"赛诺菲安万特","EQT":"EQT能源","LENZ":"Therapeutics","BK4585":"ETF&股票定投概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4539":"次新股","BK4213":"石油与天然气的勘探与生产","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"殷拓联合领投美国生物技术公司Electra Therapeutics 1.83亿美元融资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQT":1.5,"LENZ":1.5,"NXSL":0.9,"SNY":0.9},"content_text":"By Dominic Chopping \n\n\n \n\n\n  STOCKHOLM--Swedish buyout group EQT co-led a $183 million series C financing round in U.S. biotechnology company Electra Therapeutics. \n\n\n  The financing was co-led by Nextech, with participation from new investors Sanofi, HBM Healthcare Investments, Mubadala Capital, and all existing investors. \n\n\n  Electra Therapeutics is developing new medicines for people with serious immunological and cancer-related diseases, with its lead product candidate, ELA026, in development to treat secondary hemophagocytic lymphohistiocytosis--a potentially fatal hyperinflammatory disease. \n\n\n  Proceeds from the fundraise will finance a further study of the treatment and support evaluation of the drug in blood cancers, as well as another treatment that has potential across immunology and inflammation. \n\n\n \n\n\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2025 08:22 ET (12:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}